Welcome to our dedicated page for Dbv Technologies SEC filings (Ticker: DBVTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DBV Technologies S.A.'s SEC filings document a foreign issuer reporting framework for ordinary shares and American Depositary Shares. Form 8-K reports furnish financial results and business highlights, disclose registered securities, and record material governance and compensation actions.
Proxy materials for DBV Technologies S.A. cover shareholder voting matters, board authorization, compensation committee recommendations and equity award authority under French corporate law. The filings also identify ADS terms in which each American Depositary Share represents five ordinary shares, with the ADSs registered on Nasdaq under DBVT.
DBV Technologies S.A. provided an update on its planned Biologics License Application (BLA) seeking U.S. marketing approval for the VIASKIN® Peanut Patch in children aged four through seven years. After detailed, collaborative discussions with the FDA on data organization and formatting, the agency has not requested additional data. DBV will use the feedback to refine the submission and now anticipates filing the BLA in the third quarter of 2026. The company will discuss the update on a conference call and webcast on June 29 at 5:00 p.m. ET.
DBV Technologies S.A. provided an update on its planned Biologics License Application (BLA) seeking U.S. marketing approval for the VIASKIN® Peanut Patch in children aged four through seven years. After detailed, collaborative discussions with the FDA on data organization and formatting, the agency has not requested additional data. DBV will use the feedback to refine the submission and now anticipates filing the BLA in the third quarter of 2026. The company will discuss the update on a conference call and webcast on June 29 at 5:00 p.m. ET.
DBV Technologies S.A. approved a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 4,060,000 Performance Share Units (PSUs). Each PSU is a conditional right to receive one ordinary share.
Vesting depends on FDA approval of biologics license applications for Viaskin Peanut in specified age groups and a continued employment condition through July 1, 2028. PSUs that do not meet performance conditions by this date are forfeited. Vested shares are scheduled for delivery in four installments on July 1, 2028, January 1, 2029, July 1, 2029 and January 1, 2030.
Upon a Change in Control, performance conditions are deemed achieved and only the employment condition remains. The plan includes special rules for death, disability, qualifying retirement, termination without cause or for good reason, Section 409A deferral for specified employees, and allows the Board to substitute equivalent cash if the CEO is not a French tax resident at delivery.
DBV Technologies S.A. approved a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 4,060,000 Performance Share Units (PSUs). Each PSU is a conditional right to receive one ordinary share.
Vesting depends on FDA approval of biologics license applications for Viaskin Peanut in specified age groups and a continued employment condition through July 1, 2028. PSUs that do not meet performance conditions by this date are forfeited. Vested shares are scheduled for delivery in four installments on July 1, 2028, January 1, 2029, July 1, 2029 and January 1, 2030.
Upon a Change in Control, performance conditions are deemed achieved and only the employment condition remains. The plan includes special rules for death, disability, qualifying retirement, termination without cause or for good reason, Section 409A deferral for specified employees, and allows the Board to substitute equivalent cash if the CEO is not a French tax resident at delivery.
DBV Technologies S.A. reported the results of its Annual Combined Meeting of Shareholders and related changes to its bylaws. Shareholders approved amendments to Articles 18 and 21 to align the Ordinary Share Record Date with French decree nº2026-94 of February 13, 2026. They also amended Article 15 to set a Chief Executive Officer age limit of 70 years, with the CEO’s mandate ending at the shareholders’ meeting approving the financial statements for the year in which that age is reached. Across the ordinary and extraordinary agendas, the thirty-nine proposals received strong support, with many resolutions attracting around 190 million votes in favor versus much smaller opposition, confirming broad shareholder backing for the updated governance framework.
DBV Technologies S.A. reported the results of its Annual Combined Meeting of Shareholders and related changes to its bylaws. Shareholders approved amendments to Articles 18 and 21 to align the Ordinary Share Record Date with French decree nº2026-94 of February 13, 2026. They also amended Article 15 to set a Chief Executive Officer age limit of 70 years, with the CEO’s mandate ending at the shareholders’ meeting approving the financial statements for the year in which that age is reached. Across the ordinary and extraordinary agendas, the thirty-nine proposals received strong support, with many resolutions attracting around 190 million votes in favor versus much smaller opposition, confirming broad shareholder backing for the updated governance framework.
DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.
DBV Technologies S.A. ownership update: MPM BioImpact LLC reports beneficial ownership of 26,066,806 Ordinary Shares, equal to 8.8% of the outstanding Ordinary Shares. The filing states the outstanding Ordinary Shares were 296,042,447 as of March 31, 2026. The report is signed by Christopher Wolf, Chief Financial Officer.
Adage Capital Management and associated reporting persons report beneficial ownership of 22,272,884 Ordinary Shares of DBV Technologies S.A., representing 7.31% of the class based on March 25, 2026 outstanding share data. The percentage is calculated using 296,042,447 Ordinary Shares outstanding and assumes conversion of Ordinary Shares issuable upon conversion of shares of convertible preferred stock issuable upon exercise of warrants.
The filing names Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as reporting persons and discloses shared voting and dispositive power of 22,272,884 shares. Each ADS represents 5 Ordinary Shares under the CUSIP 23306J309.
Adage Capital Management and associated reporting persons report beneficial ownership of 22,272,884 Ordinary Shares of DBV Technologies S.A., representing 7.31% of the class based on March 25, 2026 outstanding share data. The percentage is calculated using 296,042,447 Ordinary Shares outstanding and assumes conversion of Ordinary Shares issuable upon conversion of shares of convertible preferred stock issuable upon exercise of warrants.
The filing names Adage Capital Management, L.P., Robert Atchinson and Phillip Gross as reporting persons and discloses shared voting and dispositive power of 22,272,884 shares. Each ADS represents 5 Ordinary Shares under the CUSIP 23306J309.
DBV TECHNOLOGIES S.A. reported that Artisan Partners entities jointly beneficially own 2,219,386 American Depositary Shares, equal to 3.7% of the class. The filing states this stake is based on 59,208,489 shares outstanding as of 03/25/2026 and lists shared voting and dispositive powers.
The Schedule 13G/A is a joint filing by Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership and includes a joint filing agreement dated 05/13/2026.
DBV TECHNOLOGIES S.A. reported that Artisan Partners entities jointly beneficially own 2,219,386 American Depositary Shares, equal to 3.7% of the class. The filing states this stake is based on 59,208,489 shares outstanding as of 03/25/2026 and lists shared voting and dispositive powers.
The Schedule 13G/A is a joint filing by Artisan Partners Asset Management Inc., Artisan Partners Holdings LP, Artisan Investments GP LLC and Artisan Partners Limited Partnership and includes a joint filing agreement dated 05/13/2026.
DBV Technologies S.A. ownership disclosure: Vivo Opportunity entities report beneficial ownership positions in the issuer's Ordinary Shares represented by ADSs. Vivo Opportunity, LLC and its affiliated Delaware partnership report 11,820,005 Ordinary Shares (represented by 2,364,001 ADSs), equal to 4.0% of shares.
Related Cayman entities report 1,517,840 Ordinary Shares (represented by 303,568 ADSs), equal to 0.5%. The percent calculations use 296,042,447 Ordinary Shares outstanding as of April 30, 2026.
DBV Technologies S.A. ownership disclosure: Vivo Opportunity entities report beneficial ownership positions in the issuer's Ordinary Shares represented by ADSs. Vivo Opportunity, LLC and its affiliated Delaware partnership report 11,820,005 Ordinary Shares (represented by 2,364,001 ADSs), equal to 4.0% of shares.
Related Cayman entities report 1,517,840 Ordinary Shares (represented by 303,568 ADSs), equal to 0.5%. The percent calculations use 296,042,447 Ordinary Shares outstanding as of April 30, 2026.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies S.A. adopted a new 2026 Performance Share Unit Plan and granted its CEO, Daniel Tassé, 1,740,000 Performance Share Units (PSUs) effective May 5, 2026. Each PSU is a conditional right to receive one ordinary share.
Half of the PSUs depend on each of two performance conditions tied to U.S. FDA acceptance for review or approval of biologics license applications for Viaskin Peanut, plus a continued employment requirement through July 1, 2028. Unmet PSUs by that date are forfeited. Vested shares are scheduled for delivery in four installments from July 1, 2028 through January 1, 2030, with change-in-control, death, disability, qualifying retirement and certain terminations receiving tailored treatment under the Plan, including potential cash settlement if the CEO is not a French tax resident.
DBV Technologies S.A. Schedule 13G/A amendment shows institutional holders led by Invus entities reporting beneficial ownership stakes in the issuer. Invus Public Equities beneficially held 17,997,870 ordinary shares as of March 31, 2026, representing 6.1% of the class. The filing states 296,042,447 shares outstanding as of March 25, 2026 (source: the issuer's Form 10-K).
The filing aggregates related parties and control links: Invus PE Advisors, Global Management, Siren, Avicenna entities, Ulys, and Raymond Debbane are disclosed as reporting persons or controlling entities; Mr. Debbane is the signing reporting person.
DBV Technologies S.A. Schedule 13G/A amendment shows institutional holders led by Invus entities reporting beneficial ownership stakes in the issuer. Invus Public Equities beneficially held 17,997,870 ordinary shares as of March 31, 2026, representing 6.1% of the class. The filing states 296,042,447 shares outstanding as of March 25, 2026 (source: the issuer's Form 10-K).
The filing aggregates related parties and control links: Invus PE Advisors, Global Management, Siren, Avicenna entities, Ulys, and Raymond Debbane are disclosed as reporting persons or controlling entities; Mr. Debbane is the signing reporting person.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.
DBV Technologies reported first quarter 2026 results showing higher spending as it prepares for potential commercialization of its VIASKIN Peanut patch. Net loss widened to $47.6 million from $27.1 million a year earlier as research, sales, and administrative expenses increased sharply.
Research and development expenses rose to $33.4 million, while sales and marketing and general and administrative costs climbed to $4.8 million and $10.5 million, respectively. Despite the larger loss, basic and diluted net loss per share improved from $(0.26) to $(0.11) due to a strengthened equity base.
DBV ended March 31, 2026 with $229 million in cash and cash equivalents, up from $194 million at year-end 2025, supported by $89 million of financing cash flows from warrant exercises. Management currently expects this cash to fund operations into the second quarter of 2027.